Quantum Genomics Announces Interim Analysis from Study of Firibastat in Renal Failure Patients Firibastat could be used in hypertensive and heart failure patients with concomitant renal dysfunction, subject to dose adjustment READ THE PRESS RELEASE Quantum Genomics Provides Update on the Impact of the COVID-19 Health Crisis on Clinical Research Activities Together with their partners, Quantum Genomics is taking all necessary measures to maintain its clinical development activities while ensuring that the safety of its staff and enrolled patients remains its top priority. READ THE PRESS RELEASE Quantum Genomics Secured New Financing, Published its Financial Statements for Fiscal Year 2019 and Provides 2019 Highlights Given the current public health crisis, and in order to prepare for its financial consequences, Quantum Genomics (the “Company”) has secured new financing thanks to an agreement with Negma Group Ltd READ THE PRESS RELEASE Quantum Genomics Initiates its Pivotal Phase III FRESH Trial in Difficult-to-Treat and Resistant Hypertension Quantum Genomics announced the initiation of its pivotal Phase III FRESH study (Firibastat in treatment-RESistant Hypertension) in difficult-to-treat and resistant hypertension in partnership with Biolab Sanus Pharmaceuticals. READ THE PRESS RELEASE Quantum Genomics and Biolab Sanus Pharmaceutical have signed an exclusive agreement for firibastat in Latin America Quantum Genomics has granted an exclusive license to Biolab Sanus Pharmaceutical to develop and commercialize firibastat for the treatment of hypertension in Latin America. READ THE PRESS RELEASE
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.